Recruiting studies: C3 Glomerulopathy

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN
Phase 2 · 6 location(s) · Omeros Corporation · NCT06209736 Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
Phase 3 · 87 location(s) · Novartis Pharmaceuticals · NCT04817618 Home Reported Outcomes in C3G Study
Phase N/A · 1 location(s) · Novartis Pharmaceuticals · NCT07029542 Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy
Phase 2 · 4 location(s) · Region Skane · NCT04183101 A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy
Phase N/A · 3 location(s) · Novartis Pharmaceuticals · NCT07416162 Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
Phase 3 · 53 location(s) · Novartis Pharmaceuticals · NCT03955445 National Registry of Rare Kidney Diseases
Phase N/A · 1 location(s) · UK Kidney Association · NCT06065852 A Clinical Trial to Test the Safety, Tolerability, and How the Body Processes CPV-104 in Healthy People and Patients Wit
Phase 1 · 16 location(s) · eleva GmbH · NCT07483827

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.